Navigation Links
Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications
Date:9/22/2010

ighly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Medicago's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Medicago or its management. The forward-looking statements are not historical facts, but reflect Medicago's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the matters discussed under "Risks Factors and Uncertainties" in Medicago's Annual Information Form filed on March 24, 2010 with the regulatory authorities. Medicago assumes no obligation to update the forward-looking statements, or to update the reaso
'/>"/>

SOURCE Medicago Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medicago named in Presidential report on meeting the challenges of pandemic influenza
2. Medicago reports positive Phase I results for its avian flu pandemic vaccine
3. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
4. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
5. Medicago begins human clinical testing with its avian flu pandemic vaccine
6. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
7. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
8. Medicago succesfully expresses VLP antigen for A H1N1 strain
9. Medicago initiates work on Swine Flu strain
10. deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma
11. deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... (Amex: NBS ),announced today that the new Southern Florida ... Miami, is targeted to open in,September. The center is being ... of this center, NeoStem has secured a key geographic,stronghold in ... as well as a,growing sophisticated South American presence., Chester ...
... Techne Corporation,s,(Nasdaq: TECH ) consolidated net earnings ... $27.3 million or $.70 per diluted share compared,with $22.9 ... ended June 30,2007. For the fiscal year ended June ... million or $2.64 per diluted share,compared with $85.1 million ...
... Life Sciences Inc.,(TSX:PLI) ("ProMetic") announces today that ... integrated, U.S.-based, biotechnology company with respect to,the ... in ProMetic,s Protein Technology Division., In ... as well as,on-going royalties on sales of ...
Cached Biology Technology:NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide 2NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide 3Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 2Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 3Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 4Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 5Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 6Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment 2Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment 3
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... smoke for a prolonged period of time and in ... even in women who never smoked cigarettes themselves. ... could increase risk of breast cancer is one that ... at the Northern California Cancer Center,s Berkeley office. "While ...
... forest,s woodland herb population has shown that climate may ... logging, according to Purdue University research. Despite heavy ... ago, the distribution of trillium plants on the secondary ... Michael Jenkins, a Purdue assistant professor of forestry and ...
... Georgia College of Veterinary Medicine have made an ... for treating Ichthyophthirius multifiliis, or "Ich", a devastating ... With the aid of whole-genome sequencing, researchers ... bacteria: Bacteroides, which are usually found free-living, ...
Cached Biology News:Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2Study finds logging effects vary based on a forest's history, climate 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3
Human peripheral blood CD14+ monocytes, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Yeast tRNA 50 l...
Human monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: